CGTX - Cognition Therapeutics wins $10M NIH grant to study lead asset in dementia

• The National Institute of Health (NIH) awarded Cognition Therapeutics ( NASDAQ: CGTX ), a clinical-stage pharma focused on age-related degenerative diseases, more than $10M grant on Monday to further support a Phase 2 trial for the company's lead asset CT1812 in dementia.
• The randomized, double-blind, placebo-controlled, parallel-group trial will be designed to evaluate the safety and efficacy of CT1812 in subjects with dementia with Lewy bodies.
• The National Institute on Aging, a division of the NIH, has awarded the grant, further expanding the agency's collaboration with Cognition ( CGTX ).
• The company has received nearly $168.9M in total grants, mainly from the NIA, including ~$81.0M to test CT1812 in a Phase 2 study involving patients with early-stage Alzheimer's disease.
• Early this month, Cognition ( CGTX ) announced biomarker data for CT1812 highlighting the potential of the oral once-daily treatment in Alzheimer's disease.

For further details see: